# GPT-5.6 Terra / mol-r01

Original final answer, shared by both scoring rounds.

## Recommended decisive question

**Can the cleavage-equivalent GSDMD amino-terminal domain, rigorously purified and free of other cellular components, directly permeabilize a chemically defined lipid bilayer; or does membrane failure require a second cellular component that is activated or recruited by the amino-terminal domain?**

The most decisive first experiment is therefore a **protein-free membrane reconstitution** using purified active amino-terminal GSDMD, followed—if needed—by **functional complementation with cellular fractions** and then **cellular epistasis/rescue**.

A positive result in a rigorously defined system would show that the amino-terminal domain is **sufficient for direct membrane action**. A negative result would not by itself prove an indirect mechanism, because the relevant membrane composition or protein state may be missing; it becomes persuasive evidence for an effector only if a cellular fraction reproducibly restores activity and the responsible factor can be depleted and re-added.

---

# 1. Evidence-to-inference-to-conclusion chain

| Evidence from packet | Inference justified | Conclusion not yet justified |
|---|---|---|
| **E1.** “A genetic screen identifies GSDMD as necessary for inflammatory-caspase-associated lytic death in the tested cells.” | GSDMD is required in this cellular death pathway under the tested conditions. | GSDMD itself need not be the physical membrane-disrupting agent; it could act through another factor. |
| **E2.** “Proteolytic cleavage separates two domains.” | Proteolysis changes GSDMD molecular state. | The cleavage product’s biochemical activity is not established. |
| **E3.** “The liberated amino-terminal domain can induce cell death, whereas the intact protein is autoinhibited.” | The amino-terminal domain is an activated death-inducing species, and the intact protein restrains that activity. | “Induce cell death” does not establish whether the domain directly damages lipid membranes or activates another cellular effector. |
| **E4.** “Cytokine processing and cytokine release can be separated experimentally.” | Cytokine release cannot be used as a mandatory proxy for the physical mechanism of lytic membrane failure. | Cytokines cannot be assumed to mediate, or not mediate, death without separate tests. |
| **E5.** “The supplied evidence does not determine the physical mechanism by which the active domain compromises membrane integrity.” | The direct-versus-effector question remains open. | No claim that GSDMD forms a pore, acts as a detergent, or activates a specific protein is presently supported. |

**Working conclusion:** cleavage is an activation switch for GSDMD, but the packet does not establish the downstream physical mechanism. The required next evidence is a sufficiency test in the absence of all other cellular components.

---

# 2. Competing mechanisms and discriminating predictions

## Mechanism A: direct membrane action

The liberated amino-terminal domain binds, inserts into, oligomerizes on, or otherwise physically destabilizes a lipid bilayer. Under this model, membrane lipids may be required, but **no second cellular protein or soluble cellular factor is required**.

### Predictions
1. Purified amino-terminal domain causes permeability of defined, protein-free liposomes or planar bilayers.
2. Activity tracks with the amino-terminal domain across independent purifications and fractionation.
3. Intact autoinhibited GSDMD is inactive or much less active under matched conditions.
4. Orthogonal physical assays show membrane association and/or membrane lesions or conductive pathways.
5. Removing a candidate cellular effector does not abolish the amino-terminal domain’s membrane-permeabilizing activity in cells, although such factors could still modulate kinetics or threshold.

## Mechanism B: indirect activation of another cellular effector

The amino-terminal domain causes lytic death by activating, recruiting, releasing, or derepressing another cellular component. That component—not the amino-terminal domain alone—physically compromises the membrane.

### Predictions
1. Purified amino-terminal domain is inactive in protein-free defined membranes over a validated, nonaggregating concentration range.
2. Activity appears only when a cell-derived fraction, membrane protein, soluble protein, enzyme, or other cellular factor is supplied.
3. The activity-restoring fraction can be biochemically tracked.
4. Depletion of the identified effector blocks lysis downstream of GSDMD cleavage while preserving amino-terminal-domain production.
5. Re-expression or re-addition of the effector restores lysis.

## Mechanism C: hybrid mechanism

The amino-terminal domain has intrinsic membrane activity, but a cellular factor amplifies, localizes, stabilizes, or regulates it.

### Predictions
1. Defined membranes show direct but possibly weak, lipid-selective, or high-threshold activity.
2. Loss of a cellular factor changes lysis kinetics, extent, localization, or threshold without eliminating the minimal-system activity.
3. The factor may be important physiologically even though it is not strictly required for physical membrane disruption in vitro.

This hybrid outcome is important: evidence of direct activity does **not** prove that no other cellular factor contributes in cells.

---

# 3. Staged study design

## Stage 0 — Reagent definition and assay qualification

### Purpose and causal role
This stage prevents an uninterpretable reconstitution experiment. If the protein preparation is not the authentic active amino-terminal product, or contains a contaminating membrane-active factor, either a positive or negative result could be misleading.

### 0A. Define the active amino-terminal reagent

Generate two independent preparations:

1. **Cleavage-derived amino-terminal domain**
   - Produce full-length GSDMD.
   - Cleave it with the relevant upstream proteolytic system only if that system and its conditions are independently defined for the tested model.
   - Purify the liberated amino-terminal domain away from intact protein, carboxyl-terminal domain, and protease.

2. **Recombinant cleavage-equivalent amino-terminal domain**
   - Express the amino-terminal sequence corresponding to the experimentally mapped cleavage product.
   - Remove purification tags before membrane testing, or demonstrate that the tag does not alter membrane binding or lytic activity.

### Required characterization
For both preparations:

- Confirm molecular identity and termini by an appropriate peptide-mapping or mass-based method.
- Confirm purity by denaturing gel analysis and an orthogonal native-size method.
- Determine whether the protein is monodisperse or aggregated under assay buffer conditions.
- Test a matched purification blank from cells carrying an empty expression construct.
- Verify that the preparation retains the reported cellular death-inducing property when delivered or expressed in the original cellular context, before interpreting a negative membrane assay.

### Essential controls
- Full-length intact GSDMD, equimolar to amino-terminal domain.
- Purified carboxyl-terminal domain if available.
- Mock cleavage reaction processed identically but lacking cleavable GSDMD.
- Protease-only control if proteolytic cleavage was used.
- Heat-inactivated or deliberately denatured amino-terminal protein, interpreted cautiously because denaturation can itself change aggregation.
- Buffer-only and purification-blank controls.

### Missing parameters requiring validation
The evidence packet does not provide:

- exact cleavage position;
- amino-terminal fragment boundaries;
- expression system;
- purification scheme;
- protein concentration;
- protein-to-lipid ratio;
- buffer composition, pH, ionic strength, or temperature;
- acceptable aggregation threshold;
- cellular level of active amino-terminal domain.

These must be measured and reported prospectively rather than inferred. The cleavage-derived and recombinant products should be tested independently because one preparation alone cannot exclude an active contaminant.

---

## Stage 1 — Minimal protein-free membrane reconstitution

### Central experiment

Test whether purified amino-terminal GSDMD causes permeability of **chemically defined, protein-free lipid vesicles**.

### Minimal system

Prepare unilamellar lipid vesicles containing entrapped soluble fluorescent tracers. Use at least two tracer sizes so that the experiment distinguishes broad membrane leakage from selective passage of smaller solutes.

Construct a limited lipid-composition matrix:

1. a simple neutral phospholipid membrane;
2. a membrane containing an anionic lipid component;
3. a membrane containing sterol or other membrane-ordering lipid;
4. mixed membranes spanning a rational range of charge and order.

The purpose is not to claim that any mixture recreates the native cell membrane. It is to ask whether amino-terminal GSDMD has direct activity against any defined bilayer and whether activity depends on membrane composition.

### Protocol

1. Prepare vesicles with defined lipid composition and confirm vesicle size distribution and tracer retention before protein addition.
2. Remove unencapsulated tracer.
3. Add amino-terminal GSDMD across a concentration series and measure tracer release over time.
4. Run matched wells containing:
   - buffer only;
   - full-length GSDMD;
   - carboxyl-terminal domain, if available;
   - cleavage-protease-only preparation;
   - mock-purification blank;
   - denatured amino-terminal domain;
   - a validated membrane-disrupting positive control to show that the vesicles and reporter can detect permeabilization.
5. Normalize leakage to complete tracer release induced at the end of the assay by a validated membrane-solubilizing control, while retaining raw fluorescence traces for inspection.
6. Repeat using the independently prepared recombinant and cleavage-derived amino-terminal proteins.
7. Measure both time dependence and concentration dependence. Report the molar protein-to-lipid ratio, not only protein mass.

### Primary readout

**Tracer release from protein-free vesicles.**

This is the key causal test:

- If amino-terminal GSDMD alone causes reproducible leakage while all negative controls remain intact, then it is sufficient for direct membrane permeabilization under those conditions.
- If activity requires added cell material, direct sufficiency is not demonstrated.

### Interpretation safeguards

A positive result is credible only if:

- activity is reproduced with independently generated amino-terminal proteins;
- activity follows the amino-terminal protein during purification;
- mock preparations and protease-only controls are inactive;
- the protein is not simply present as nonspecific precipitated aggregate;
- intact GSDMD does not show equivalent activity at matched molar input.

A finding that only one lipid mixture is susceptible would still support direct membrane action, but specifically **lipid-dependent** direct action.

---

## Stage 2 — Orthogonal physical measurements

Tracer release alone demonstrates permeability, not the physical route. The following measurements should be applied to the same active protein preparations and lipid compositions.

## 2A. Membrane binding assay

Measure whether amino-terminal GSDMD partitions with vesicles by flotation, co-sedimentation, or fluorescently labeled protein imaging.

### Causal interpretation
- Binding without leakage means membrane association is insufficient for disruption.
- Leakage without detectable stable binding may indicate transient interactions, insufficient assay sensitivity, or an artifact; this outcome requires further validation.
- Concordant binding and leakage across lipid compositions supports a direct lipid-bilayer interaction.

## 2B. Planar-bilayer electrical recording

Expose a protein-free planar lipid bilayer to amino-terminal GSDMD and record membrane conductance.

### Causal interpretation
- Increased conductance in the absence of other cellular components independently supports direct creation of ion-permeable pathways.
- Discrete conductance events would be consistent with defined membrane lesions or channels, but would not by themselves establish molecular architecture.
- A gradual unstable conductance increase could reflect generalized membrane destabilization rather than a defined pore.
- No conductance despite tracer release may reflect differences in lipid composition, tracer size, lesion lifetime, or assay sensitivity.

## 2C. Structural membrane analysis

Use cryogenic imaging, electron microscopy, atomic-force microscopy, or another structural method appropriate to the membrane preparation.

### Causal interpretation
- Visible membrane discontinuities, altered membrane morphology, or protein-associated lesions would support physical membrane action.
- Absence of visible lesions does not exclude small, transient, or low-abundance permeabilizing structures.
- Structural observations must be interpreted together with leakage and conductance, not alone.

### Decision value of Stage 2
Agreement among leakage, protein–membrane association, and electrical or structural evidence makes a contaminating or assay-specific explanation much less likely than any one assay alone.

---

## Stage 3 — Conditional effector discovery by functional complementation

This stage is essential if Stage 1 is negative, weak, or only active at clearly nonphysiological/aggregating protein conditions.

### Question

**Can a cellular fraction restore membrane permeabilization by amino-terminal GSDMD in a system where defined lipids and amino-terminal domain alone are inactive?**

### Protocol

1. Prepare cytosolic, membrane-enriched, and other operationally separated fractions from the tested cells or a closely matched GSDMD-deficient derivative.
   - Using GSDMD-deficient cells reduces the risk that endogenous activated GSDMD contaminates the fractions.
2. Confirm that fractions alone do not cause reporter release.
3. Add each fraction, or defined combinations of fractions, to the otherwise inactive amino-terminal-domain-plus-liposome assay.
4. Identify the fraction that restores leakage.
5. Subfractionate the active material while tracking reconstituted activity at every step.
6. Test whether activity is sensitive to:
   - protein depletion;
   - heat treatment;
   - protease treatment;
   - small-molecule removal or retention;
   - loss of membrane components.
   
   These treatments are classificatory, not definitive, because they can damage cofactors or membrane organization.
7. Identify candidate components in active versus inactive fractions.
8. Test candidate necessity by selective depletion from the active fraction.
9. Test sufficiency by adding back purified or recombinant candidate into the inactive defined system with amino-terminal GSDMD.

### Causal interpretation

The strongest evidence for an effector mechanism would be:

1. amino-terminal GSDMD alone is inactive in validated defined membranes;
2. a reproducible cellular fraction restores activity;
3. activity tracks with one candidate through fractionation;
4. removing that candidate abolishes reconstituted activity;
5. adding it back restores activity; and
6. loss of the same candidate blocks lysis in cells without preventing GSDMD cleavage.

This sequence would establish that the candidate is not merely associated with the process, but is functionally required downstream of activated GSDMD.

### Important limitation

If no fraction restores activity, the result is ambiguous. It could mean that the amino-terminal domain is inactive, the membrane composition is wrong, the effector was lost or denatured during fractionation, or the relevant process requires cellular architecture.

---

## Stage 4 — Cellular validation and epistasis

### Goal

Determine whether the mechanism identified in reconstitution is used in the tested cellular lytic-death pathway.

### Cell system

Generate or obtain isogenic derivatives of the tested cells:

1. parental cells;
2. GSDMD-deficient cells;
3. GSDMD-deficient cells rescued with full-length GSDMD;
4. GSDMD-deficient cells rescued with cleavage-resistant full-length GSDMD;
5. GSDMD-deficient cells expressing the cleavage-equivalent amino-terminal domain;
6. if Stage 3 identifies an effector, effector-deficient versions of the relevant lines plus rescue with the effector.

The cleavage-resistant construct must be experimentally verified to remain uncleaved under the original inflammatory-caspase-associated stimulus. Exact cleavage-site substitutions cannot be specified from the packet and must be based on Stage 0 mapping.

### Measurements

Measure, in the same time-resolved experiment:

- GSDMD cleavage and amino-terminal-domain abundance;
- loss of plasma-membrane integrity, using entry of a normally excluded reporter;
- release of intracellular contents as an independent lytic readout;
- cell morphology and timing of lysis;
- cytokine processing inside cells;
- cytokine release into the medium.

### Why cytokines must be measured separately

The packet states that cytokine processing and cytokine release can be experimentally separated. Therefore:

- cytokine processing should be used as an indicator that upstream inflammatory processing can occur;
- cytokine release should not be treated as proof of membrane permeabilization;
- loss of cytokine release after blocking lysis may simply reflect reduced membrane escape rather than loss of cytokine processing.

### Direct-mechanism cellular prediction

If reconstitution establishes direct membrane action, then amino-terminal-domain expression should induce membrane-permeability phenotypes in GSDMD-deficient cells, whereas intact full-length GSDMD should remain restrained unless cleaved. Loss of an identified modifier may alter the threshold or timing but should not eliminate direct reconstitution activity.

### Effector-mechanism cellular prediction

If a candidate effector is identified, its depletion should:

- preserve GSDMD expression and cleavage;
- preserve or at least separately document upstream cytokine processing;
- reduce membrane permeability and lytic death;
- be reversed by re-expression of the effector;
- ideally show the same requirement in the cell-free complementation assay.

An effector knockout that prevents GSDMD cleavage cannot be interpreted as a downstream membrane effector; it may act upstream.

---

# 4. Explicit possible outcomes and conclusions

| Outcome | Conclusion justified | What remains uncertain |
|---|---|---|
| Purified amino-terminal GSDMD reproducibly permeabilizes protein-free defined membranes; full-length protein and purification controls do not; conductance and binding support the result. | The amino-terminal domain is sufficient for direct membrane permeabilization. | Whether this is the dominant mechanism in cells; whether a cellular factor regulates it. |
| Amino-terminal GSDMD is active only with selected defined lipid mixtures. | Direct activity is lipid-composition dependent. | Whether those lipids are accessible in the relevant cellular membrane. |
| Amino-terminal GSDMD is inactive alone but active after one cellular fraction is added; candidate depletion and add-back reproduce loss and rescue. | The tested mechanism requires a downstream cellular effector or cofactor. | Whether the effector is directly activated by GSDMD or acts permissively. |
| Defined membranes show direct activity, but candidate-effector loss protects cells. | Hybrid mechanism: intrinsic membrane activity exists, while the cellular factor is needed for physiological efficiency, localization, or amplification. | The exact role of the factor. |
| Amino-terminal domain is inactive in vitro and inactive in cells after expression. | The reagent may be misfolded, incorrectly bounded, improperly localized, or otherwise nonfunctional. | No mechanism can be concluded. |
| Activity occurs only at concentrations associated with visible aggregation or nonspecific membrane destruction. | The protein can physically damage membranes under extreme conditions. | Physiological relevance is not established. |
| Effector depletion blocks lysis but also reduces cleavage or upstream activation. | The effector may act upstream rather than in membrane failure. | Downstream mechanism remains unresolved. |

---

# 5. Key limits and missing settings

The following settings are not supplied and should be established in pilot validation, then fixed before decisive experiments:

- lipid identities and molar compositions;
- vesicle size, lamellarity, and tracer-loading efficiency;
- buffer composition, pH, ionic strength, temperature, and incubation time;
- amino-terminal-domain concentration range and protein-to-lipid ratio;
- protein purity criteria and aggregation measurements;
- cell stimulus, dose, and timing for inflammatory-caspase-associated lysis;
- number of independent protein preparations and biological replicates;
- predefined threshold for meaningful membrane leakage or conductance;
- quantitative comparison of amino-terminal-domain abundance in reconstitution and cells;
- identity and depletion method for any discovered effector.

The most consequential uncertainty is a **false-negative minimal system**: a lack of leakage might reflect the wrong membrane composition or an inactive recombinant protein rather than a true requirement for another cellular factor. This is why functional validation of the amino-terminal reagent, a lipid-composition matrix, orthogonal physical assays, and fraction-complementation are all required before concluding that GSDMD acts indirectly.
